Key Takeaways ABBV's Emrelis is the only FDA-approved drug for high c-Met OE NSCLC. The drug broadens ABBV's oncology portfolio beyond hematologic cancers, adding diversity to its pipeline. Rivals AZN and REGN are also advancing their respective candidates targeting similar c-MET-driven cancers.AbbVie (ABBV) continues to build momentum with its oncology franchise, with the recent FDA approval for Emrelis. This antibody-drug conjugate (ADC) was granted accelerated approval last month for previously treated ...